Diagnos Stock Price, News & Analysis

DIAGNOS Inc. (OTCQB: DGNOF) is a publicly traded Canadian corporation in the information sector, associated with the software publishers industry. According to its public disclosures, DIAGNOS is dedicated to the early detection of critical health problems, with a strong focus on eye-related health issues. The company bases its approach on its proprietary FLAIRE platform, which uses Artificial Intelligence (AI) to analyze medical imaging data and support healthcare professionals.

DIAGNOS describes itself as a pioneer and leader in the early detection of critical health issues using AI. Its technology is applied to the detection of critical eye-related health problems and broader critical health issues, with the goal of enhancing diagnostic accuracy, streamlining clinical workflows, and improving patient outcomes. The company states that its solutions are intended to support healthcare clinicians by providing additional information rather than replacing medical professionals.

FLAIRE AI Platform

The core of DIAGNOS’ offering is its FLAIRE Artificial Intelligence (AI) platform. Public materials explain that FLAIRE allows for quick modifying and developing of applications. One of the key applications built on FLAIRE is CARA (Computer Assisted Retina Analysis). DIAGNOS describes CARA as a tool whose enhancement algorithms provide sharper, clearer, and easier-to-analyze retinal images. The company states that CARA is designed as a cost-effective tool for real-time screening of large volumes of patients, which is particularly relevant in mass screening contexts.

DIAGNOS also reports that it has developed 3D image analysis technology for the retinal diagnostics market. This technology uses deep learning-powered methods to support diagnosis of retinal conditions. The company has indicated that it is entering the retinal diagnostics market with this 3D analysis capability.

Focus on Eye Health and Retinal Diagnostics

Public communications from DIAGNOS emphasize its focus on eye health and retinal diagnostics. The company highlights the use of its AI technology for early detection and follow-up of various ocular diseases. In collaboration with partners, DIAGNOS has worked on screening programs and algorithm training based on retinal images and optical coherence tomography (OCT) data.

DIAGNOS has stated that its technology is capable of supporting diagnosis of retinal conditions such as Age-Related Macular Degeneration, Diabetic Retinopathy, Glaucoma, Macular Edema, Retinal Cancer, and other retinal and macular diseases. The company also notes that neurological and systemic diseases affecting other parts of the body can be identified through retinal analysis, including conditions such as Alzheimer’s disease, cardiovascular diseases, multiple sclerosis, and Parkinson’s disease, based on the multimodal data analysis tools it has developed.

CARA and Regulatory Clearances

In its disclosures, DIAGNOS reports that its CARA (Computer Assisted Retina Analysis) application has obtained regulatory clearances for commercialization from multiple authorities. CARA has been cleared by Health Canada, the U.S. Food and Drug Administration (FDA), CE (Europe), COFEPRIS (Mexico), and the Saudi Food and Drug Authority (Saudi FDA). These clearances relate to the use of CARA as a medical device for retinal image analysis and screening.

DIAGNOS also references a Medical Device Single Audit Program (MDSAP) audit in its public statements, indicating that it has undergone regulatory-related audits as part of its activities. The company has mentioned pending regulatory approvals from authorities such as the Saudi FDA, Health Canada and the FDA in connection with its growth plans, while also noting that forward-looking statements are subject to uncertainty.

Research, Partnerships, and Clinical Context

DIAGNOS has highlighted several collaborations and research initiatives in its public news releases. In partnership with IRIS, The Visual Group, the company launched “IRIS-ai powered by DIAGNOS.” Over a multi-year period, IRIS and DIAGNOS worked together to combine technological innovation with front-line clinical experience to improve patient care through early detection and follow-up of ocular diseases. According to DIAGNOS, approximately 14,000 patients across Quebec were screened in this collaboration, creating a databank of retinal images reflecting the diversity of patients in the province. IRIS optometrists contributed annotations and clinical validation to train and confirm the relevance and accuracy of DIAGNOS’ algorithms.

Under the Quebec Ministry of Economy, Innovation and Energy’s INVEST-AI initiative, DIAGNOS and IRIS submitted a pilot program and later received a subsidy to adapt the AI technology in a commercial context. DIAGNOS has also indicated that the “IRIS-ai powered by DIAGNOS” solution is being deployed in Quebec and is planned for gradual introduction to IRIS locations across Canada.

In another collaboration, DIAGNOS and École de Technologie Supérieure (ÉTS) reported ground-breaking research on mass screening for macular edema using OCT at the ARVO (Association for Research in Vision and Ophthalmology) annual conference. The company describes this research as a major advancement in medical imaging, emphasizing algorithm efficiency, fidelity of a “heat map” type decision-making tool, and a very low rate of false positives in screening for macular edema.

OCT and Multimodal Data Analysis

DIAGNOS’ public materials describe the use of Optical Coherence Tomography (OCT) and retinal imaging as core data sources. The company states that its multimodal data analysis tools combine data from retinal images and OCT scans to support retinal diagnostics. DIAGNOS has characterized its technology as non-invasive and integrating analysis of 3D cross-sectional images of the retina. In its description of the retinal diagnostics market, the company notes that its approach uses highly accurate technologies for retinal diagnostics.

Market Orientation and Industry Positioning

DIAGNOS operates in the context of the retinal diagnostics and medical imaging markets, with a focus on AI-driven analysis. Public statements from the company refer to the retinal diagnostics market as fast-growing and describe factors such as technological advancements in diagnostic methods, evolving healthcare infrastructure, adoption of advanced retinal imaging systems, and healthcare reimbursement policies as relevant to the category. DIAGNOS has indicated that these factors contributed to its decision to enter the retinal diagnostics market with its 3D image analysis technology.

The company has also referenced the optometry market, noting that it comprises a large number of sites globally, and has mentioned a partnership with what it describes as a major player in the industry. DIAGNOS states that this partnership has validated its technology and increased its visibility. In addition, the company has referred to government-related business initiatives that it characterizes as resuming, which it associates with a phase of growth.

Corporate and Trading Information

DIAGNOS identifies itself as a publicly traded Canadian corporation. Its shares are referenced as trading on the TSX Venture Exchange under the symbol ADK, on the OTCQB under the symbol DGNOF, and on the Frankfurt Stock Exchange under the symbol 4D4A, according to its news releases. The company indicates that additional corporate and regulatory information is available through Canadian securities platforms such as SEDAR or SEDAR+.

DIAGNOS’ communications also include standard cautionary language regarding forward-looking information, emphasizing that actual results and future events may differ materially from expectations and that the company has no obligation to update such information except as required by law.

Key Concepts and Technologies

• FLAIRE AI Platform: The foundation for DIAGNOS’ AI-based medical imaging applications, used to develop and modify tools for health problem detection.
• CARA (Computer Assisted Retina Analysis): An application built on FLAIRE, described as providing enhanced retinal images and supporting real-time screening of large patient volumes.
• 3D Retinal Image Analysis: Technology used by DIAGNOS to analyze 3D cross-sectional retinal images, particularly in the retinal diagnostics market.
• OCT-Based Screening: Use of Optical Coherence Tomography data in combination with retinal images for mass screening of conditions such as macular edema.
• AI-Enabled Decision Support: Algorithms and tools, including heat map-type decision aids, intended to assist healthcare professionals in interpreting imaging results.

FAQs about DIAGNOS Inc. (DGNOF)

• What does DIAGNOS Inc. do?
  

  DIAGNOS Inc. is a publicly traded Canadian corporation focused on the early detection of critical health problems, particularly eye-related conditions. It uses its FLAIRE Artificial Intelligence platform and applications such as CARA (Computer Assisted Retina Analysis) to analyze retinal images and related data to support healthcare clinicians.

• What is the FLAIRE platform?
  

  FLAIRE is DIAGNOS’ Artificial Intelligence platform that enables quick modifying and developing of medical imaging applications. It underpins tools such as CARA, which enhance retinal images and support real-time screening of large numbers of patients for critical health issues.

• What is CARA (Computer Assisted Retina Analysis)?
  

  CARA is an application built on the FLAIRE platform. DIAGNOS describes CARA as using enhancement algorithms to produce sharper, clearer, and easier-to-analyze retinal images. It is positioned as a cost-effective tool for real-time screening of large volumes of patients for retinal and related health problems.

• Which health conditions does DIAGNOS’ technology address?
  

  According to DIAGNOS, its AI-powered retinal diagnostics technology can support diagnosis of retinal conditions such as Age-Related Macular Degeneration, Diabetic Retinopathy, Glaucoma, Macular Edema, Retinal Cancer, and other retinal and macular diseases. The company also states that neurological and systemic diseases such as Alzheimer’s disease, cardiovascular diseases, multiple sclerosis, and Parkinson’s disease can be identified through retinal analysis.

• What regulatory clearances has CARA obtained?
  

  DIAGNOS reports that its CARA application has been cleared for commercialization by Health Canada, the U.S. FDA, CE in Europe, COFEPRIS in Mexico, and the Saudi Food and Drug Authority. These clearances relate to CARA’s use as a medical device for retinal image analysis and screening.

• How does DIAGNOS use Optical Coherence Tomography (OCT)?
  

  DIAGNOS combines data from retinal images and OCT scans in its multimodal data analysis tools. In collaboration with ÉTS, the company has presented research on mass screening for macular edema using OCT, highlighting efficient algorithms, heat map decision tools, and a low rate of false positives.

• What is “IRIS-ai powered by DIAGNOS”?
  

  “IRIS-ai powered by DIAGNOS” is a solution launched by IRIS, The Visual Group, in partnership with DIAGNOS. It builds on DIAGNOS’ AI technology and clinical experience from IRIS optometrists to improve early detection and follow-up of ocular diseases. The partners report that thousands of patients in Quebec were screened to train and validate the algorithms.

• On which markets does DIAGNOS trade?
  

  In its public releases, DIAGNOS states that its shares trade on the TSX Venture Exchange under the symbol ADK, on the OTCQB market under the symbol DGNOF, and on the Frankfurt Stock Exchange under the symbol 4D4A.

• How does DIAGNOS describe the role of AI in healthcare?
  

  DIAGNOS’ public statements emphasize that Artificial Intelligence is intended to empower physicians by providing more information and improving accuracy and efficiency, rather than replacing doctors. The company positions its AI tools as decision support systems that can enhance patient outcomes.

• Where can investors find more information about DIAGNOS?
  

  DIAGNOS indicates that additional information about the company and its securities is available through Canadian regulatory platforms such as SEDAR or SEDAR+, as well as through its public news releases.